0001376339 12/31 2024 Q3 false September 30, 2024 xbrli:shares iso4217:USD iso4217:USD xbrli:shares mdxg:term_loan xbrli:pure mdxg:service_site mdxg:product_line 0001376339 2024-01-01 2024-09-30 0001376339 2024-10-21 0001376339 2024-09-30 0001376339 2023-12-31 0001376339 2024-07-01 2024-09-30 0001376339 2023-07-01 2023-09-30 0001376339 2023-01-01 2023-09-30 0001376339 us-gaap:CommonStockMember 2024-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001376339 us-gaap:TreasuryStockCommonMember 2024-06-30 0001376339 us-gaap:RetainedEarningsMember 2024-06-30 0001376339 2024-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001376339 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001376339 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001376339 us-gaap:CommonStockMember 2024-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001376339 us-gaap:TreasuryStockCommonMember 2024-09-30 0001376339 us-gaap:RetainedEarningsMember 2024-09-30 0001376339 us-gaap:CommonStockMember 2023-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001376339 us-gaap:TreasuryStockCommonMember 2023-06-30 0001376339 us-gaap:RetainedEarningsMember 2023-06-30 0001376339 2023-06-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001376339 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001376339 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001376339 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001376339 us-gaap:CommonStockMember 2023-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001376339 us-gaap:TreasuryStockCommonMember 2023-09-30 0001376339 us-gaap:RetainedEarningsMember 2023-09-30 0001376339 2023-09-30 0001376339 us-gaap:CommonStockMember 2023-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001376339 us-gaap:TreasuryStockCommonMember 2023-12-31 0001376339 us-gaap:RetainedEarningsMember 2023-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001376339 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001376339 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001376339 us-gaap:CommonStockMember 2022-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001376339 us-gaap:TreasuryStockCommonMember 2022-12-31 0001376339 us-gaap:RetainedEarningsMember 2022-12-31 0001376339 2022-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001376339 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001376339 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001376339 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001376339 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-12-31 0001376339 us-gaap:EquipmentMember 2024-09-30 0001376339 us-gaap:EquipmentMember 2023-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001376339 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001376339 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001376339 us-gaap:ConstructionInProgressMember 2024-09-30 0001376339 us-gaap:ConstructionInProgressMember 2023-12-31 0001376339 mdxg:AssetRetirementCostMember 2024-09-30 0001376339 mdxg:AssetRetirementCostMember 2023-12-31 0001376339 us-gaap:PatentsMember 2024-09-30 0001376339 us-gaap:PatentsMember 2023-12-31 0001376339 us-gaap:LicensingAgreementsMember 2024-09-30 0001376339 us-gaap:LicensingAgreementsMember 2023-12-31 0001376339 us-gaap:DistributionRightsMember 2024-09-30 0001376339 us-gaap:DistributionRightsMember 2023-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001376339 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001376339 mdxg:PatentsinProcessMember 2024-09-30 0001376339 mdxg:PatentsinProcessMember 2023-12-31 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember srt:MinimumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember srt:MaximumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MinimumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MaximumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-19 2024-01-19 0001376339 mdxg:DebtAmortizationYearOneMember mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:DebtAmortizationYearTwoMember mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:DebtAmortizationYearThreeMember mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:DebtAmortizationYearFourMember mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:DebtAmortizationYearFiveMember mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-01-19 2024-01-19 0001376339 mdxg:HayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2024-01-19 2024-01-19 0001376339 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-02-27 2024-02-27 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2024-09-30 0001376339 mdxg:HayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember srt:MinimumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember srt:MaximumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MinimumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MaximumMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRFallbackProvisionMember 2024-01-19 2024-01-19 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember srt:MinimumMember 2024-09-30 0001376339 mdxg:TermLoanFacilityAndHayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2024-07-01 2024-09-30 0001376339 mdxg:TermLoanFacilityAndHayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2023-07-01 2023-09-30 0001376339 mdxg:TermLoanFacilityAndHayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2024-01-01 2024-09-30 0001376339 mdxg:TermLoanFacilityAndHayfinTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2023-01-01 2023-09-30 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-07-01 2024-09-30 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-01 2024-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-09-30 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001376339 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001376339 us-gaap:PerformanceSharesMember 2023-07-01 2023-09-30 0001376339 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001376339 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001376339 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001376339 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001376339 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001376339 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001376339 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0001376339 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0001376339 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001376339 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-09-30 0001376339 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-09-30 0001376339 mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 srt:MinimumMember mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 srt:MaximumMember mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 us-gaap:DistributionRightsMember mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 us-gaap:DistributionRightsMember mdxg:TELAAPAMember 2024-03-15 0001376339 mdxg:TELAAPAMember 2024-09-30 2024-09-30 0001376339 us-gaap:SettledLitigationMember 2024-06-30 0001376339 us-gaap:SettledLitigationMember 2024-01-01 2024-09-30 0001376339 mdxg:HospitalSiteOfServiceMember 2024-07-01 2024-09-30 0001376339 mdxg:HospitalSiteOfServiceMember 2023-07-01 2023-09-30 0001376339 mdxg:HospitalSiteOfServiceMember 2024-01-01 2024-09-30 0001376339 mdxg:HospitalSiteOfServiceMember 2023-01-01 2023-09-30 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2024-07-01 2024-09-30 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2023-07-01 2023-09-30 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2024-01-01 2024-09-30 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2023-01-01 2023-09-30 0001376339 mdxg:OtherSiteOfServiceMember 2024-07-01 2024-09-30 0001376339 mdxg:OtherSiteOfServiceMember 2023-07-01 2023-09-30 0001376339 mdxg:OtherSiteOfServiceMember 2024-01-01 2024-09-30 0001376339 mdxg:OtherSiteOfServiceMember 2023-01-01 2023-09-30 0001376339 mdxg:WoundMember 2024-07-01 2024-09-30 0001376339 mdxg:WoundMember 2023-07-01 2023-09-30 0001376339 mdxg:WoundMember 2024-01-01 2024-09-30 0001376339 mdxg:WoundMember 2023-01-01 2023-09-30 0001376339 mdxg:SurgicalMember 2024-07-01 2024-09-30 0001376339 mdxg:SurgicalMember 2023-07-01 2023-09-30 0001376339 mdxg:SurgicalMember 2024-01-01 2024-09-30 0001376339 mdxg:SurgicalMember 2023-01-01 2023-09-30 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2024-07-01 2024-09-30 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2023-07-01 2023-09-30 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2024-01-01 2024-09-30 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2023-01-01 2023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the
Quarterly Period Ended
September 30, 2024
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________to______________________
Commission File Number 001-35887
MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)

Florida |  | 26-2792552
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1775 West Oak Commons Ct NE Marietta, GA |  | 30062
(Address of principal executive offices) |  | (Zip Code)

(770) 651-9100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | MDXG | The Nasdaq Stock Market

Securities registered pursuant to Section 12(g) of the Act: None.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x | Accelerated filer ¨ | Non-accelerated filer ¨ | Smaller reporting company ☐ | Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No x
There were 146,946,213 shares of the registrant’s common stock, par value $0.001 per share, outstanding as of October 21, 2024.

Table of Contents

Part I FINANCIAL INFORMATION |
Item 1 | Financial Statements (Unaudited) |
| Condensed Consolidated Balance Sheets | 5
| Condensed Consolidated Statements of Operations | 6
| Condensed Consolidated Statements of Stockholders’ Equity | 7
| Condensed Consolidated Statements of Cash Flows | 9
| Notes to the Condensed Consolidated Financial Statements | 10
Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21
Item 3 | Quantitative and Qualitative Disclosures About Market Risk | 27
Item 4 | Controls and Procedures | 28
Part II OTHER INFORMATION
Item 1 | Legal Proceedings | 29
Item 1A | Risk Factors | 29
Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 29
Item 3 | Defaults upon Senior Securities | 29
Item 4 | Mine Safety Disclosures | 29
Item 5 | Other Information | 29
Item 6 | Exhibits | 30
Signatures |  | 30

3

Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements
As used herein, the terms “MIMEDX,” the “Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.
Certain statements made in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended. All statements herein relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:
•our strategic focus and current business priorities, including broadening of our product portfolio, and our ability to implement these priorities, including as a result of our no longer being able to market certain products in our portfolio;
•our expectations regarding costs relating to compliance with regulatory requirements;
•our expectations regarding investigation, restatement and related expense;
•our expectations regarding capital allocation;
•our expectations regarding future growth;
•our expectations regarding the outcome of pending litigation and investigations;
•our expectations regarding future income tax liability;
•demographic and market trends; and
•our ability to compete effectively.
Forward-looking statements generally can be identified by words such as “expect,” “will,” “change,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “estimate,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 (our “2023 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and those discussed in Part II, Item 1A, Risk Factors, if any.
Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Quarterly Report is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Quarterly Report in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report with the SEC.
Estimates and Projections
This Quarterly Report includes certain estimates, projections and other statistical data. These estimates and projections reflect management’s best estimates based upon currently available information and certain assumptions we believe to be reasonable as of the date of this Quarterly Report. These estimates are inherently uncertain, subject to risks and uncertainties, many of which are not within our control, have not been reviewed by our independent auditors and may be revised as a result of management’s further review. In addition, these estimates and projections are not a comprehensive statement of our financial results, and our actual results may differ materially from these estimates and projections due to developments that may arise between now and the time the results are final. There can be no assurance that the estimates will be realized, and our results may vary significantly from the estimates, including as a result of unexpected issues in our business and operations. Accordingly, you should not place undue reliance on such information. Projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
4

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(unaudited)

| September 30, 2024 |  | December 31, 2023
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 88,801 |  |  | $ | 82,000 |
Accounts receivable, net | 54,030 |  |  | 53,871 |
Inventory | 24,249 |  |  | 21,021 |
Prepaid expenses | 2,907 |  |  | 5,624 |
Other current assets | 2,152 |  |  | 1,745 |
Total current assets | 172,139 |  |  | 164,261 |
Property and equipment, net | 6,451 |  |  | 6,974 |
Right of use asset | 2,843 |  |  | 2,132 |
Deferred tax asset, net | 30,636 |  |  | 40,777 |
Goodwill | 19,441 |  |  | 19,441 |
Intangible assets, net | 11,201 |  |  | 5,257 |
Other assets | 1,180 |  |  | 205 |
Total assets | $ | 243,891 |  |  | $ | 239,047 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Current portion of long term debt | $ | 1,000 |  |  | $ | 1,000 |
Accounts payable | 6,924 |  |  | 9,048 |
Accrued compensation | 20,170 |  |  | 22,353 |
Accrued expenses | 8,396 |  |  | 9,361 |
Current portion of Profit Share Payments (Note 12) | 2,860 |  |  | — |
Current liabilities of discontinued operations | — |  |  | 1,352 |
Other current liabilities | 2,591 |  |  | 2,894 |
Total current liabilities | 41,941 |  |  | 46,008 |
Long term debt, net | 18,018 |  |  | 48,099 |
Other liabilities | 2,924 |  |  | 2,223 |
Total liabilities | $ | 62,883 |  |  | $ | 96,330 |
Commitments and contingencies (Note 12) |  |  |
Stockholders' equity |  |  |
Common stock; $0.001 par value; 250,000,000 shares authorized; 146,962,812 issued and outstanding at September 30, 2024 and 146,227,639 issued and outstanding at December 31, 2023 | 147 |  |  | 146 |
Additional paid-in capital | 279,558 |  |  | 276,249 |
Accumulated deficit | (98,697) |  |  | (133,678) |
Total stockholders' equity | 181,008 |  |  | 142,717 |
Total liabilities and stockholders’ equity | $ | 243,891 |  |  | $ | 239,047 |

See notes to unaudited condensed consolidated financial statements
5

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Net sales | $ | 84,057 |  |  | $ | 81,712 |  |  | $ | 255,972 |  |  | $ | 234,645 |
Cost of sales | 15,322 |  |  | 14,790 |  |  | 43,164 |  |  | 40,792 |
Gross profit | 68,735 |  |  | 66,922 |  |  | 212,808 |  |  | 193,853 |
Operating expenses: |  |  |  |  |  |  |
Selling, general and administrative | 53,516 |  |  | 52,571 |  |  | 164,044 |  |  | 156,773 |
Research and development | 2,918 |  |  | 3,075 |  |  | 8,770 |  |  | 10,232 |
Investigation, restatement and related | 649 |  |  | (38) |  |  | (8,741) |  |  | 4,652 |
Amortization of intangible assets | 192 |  |  | 190 |  |  | 572 |  |  | 570 |
Impairment of intangible assets | 298 |  |  | — |  |  | 352 |  |  | — |
Operating income | 11,162 |  |  | 11,124 |  |  | 47,811 |  |  | 21,626 |
Other expense, net |  |  |  |  |  |  |
Interest income (expense), net | 278 |  |  | (1,680) |  |  | (1,409) |  |  | (4,864) |
Other expense, net | (21) |  |  | (11) |  |  | (357) |  |  | (42) |
Income from continuing operations before income tax provision | 11,419 |  |  | 9,433 |  |  | 46,045 |  |  | 16,720 |
Income tax provision from continuing operations | (3,541) |  |  | (591) |  |  | (11,485) |  |  | (569) |
Net income from continuing operations | 7,878 |  |  | 8,842 |  |  | 34,560 |  |  | 16,151 |
Income (loss) from discontinued operations, net of tax | 217 |  |  | (308) |  |  | 421 |  |  | (11,400) |
Net income | $ | 8,095 |  |  | $ | 8,534 |  |  | $ | 34,981 |  |  | $ | 4,751 |
Net income available to common stockholders from continuing operations | $ | 7,878 |  |  | $ | 7,069 |  |  | $ | 34,560 |  |  | $ | 10,967 |
Basic net income per common share: |  |  |  |  |  |  |
Continuing operations | 0.05 |  |  | 0.06 |  |  | 0.24 |  |  | 0.09 |
Discontinued operations | 0.00 |  |  | (0.00) |  |  | 0.00 |  |  | (0.09) |
Basic net income per common share | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.24 |  |  | $ | 0.00 |
Diluted net income per common share: |  |  |  |  |  |  |
Continuing operations | 0.05 |  |  | 0.06 |  |  | 0.23 |  |  | 0.09 |
Discontinued operations | 0.00 |  |  | (0.00) |  |  | 0.00 |  |  | (0.09) |
Diluted net income per common share | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.23 |  |  | $ | 0.00 |
Weighted average common shares outstanding - basic | 146,958,986 |  |  | 116,298,146 |  |  | 147,008,732 |  |  | 115,528,067 |
Weighted average common shares outstanding - diluted | 148,373,631 |  |  | 149,773,706 |  |  | 148,964,788 |  |  | 116,893,270 |

See notes to unaudited condensed consolidated financial statements
6

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
(unaudited)

| Common Stock Issued |  | Additional Paid- In |  | Treasury Stock |  | Accumulated |  |
| Shares |  | Amount |  | Capital |  | Shares |  | Amount |  | Deficit |  | Total
Balance at June 30, 2024 | 146,749,402 |  |  | $ | 147 |  |  | $ | 274,685 |  |  | — |  |  | $ | — |  |  | $ | (106,792) |  |  | $ | 168,040 |
Share-based compensation expense | — |  |  | — |  |  | 3,810 |  |  | — |  |  | — |  |  | — |  |  | 3,810 |
Exercise of stock options | 61,666 |  |  | — |  |  | 387 |  |  | — |  |  | — |  |  | — |  |  | 387 |
Employee stock purchase plan | 123,857 |  |  | — |  |  | 785 |  |  | — |  |  | — |  |  | — |  |  | 785 |
Issuance of restricted stock, net | 27,887 |  |  | — |  |  | (109) |  |  | — |  |  | — |  |  | — |  |  | (109) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8,095 |  |  | 8,095 |
Balance at September 30, 2024 | 146,962,812 |  |  | $ | 147 |  |  | $ | 279,558 |  |  | — |  |  | $ | — |  |  | $ | (98,697) |  |  | $ | 181,008 |

| Common Stock Issued |  | Additional Paid- In |  | Treasury Stock |  | Accumulated |  |
| Shares |  | Amount |  | Capital |  | Shares |  | Amount |  | Deficit |  | Total
Balance at June 30, 2023 | 116,109,125 |  |  | $ | 116 |  |  | $ | 182,907 |  |  | — |  |  | $ | — |  |  | $ | (195,689) |  |  | $ | (12,666) |
Share-based compensation expense | — |  |  | — |  |  | 4,388 |  |  | — |  |  | — |  |  | — |  |  | 4,388 |
Exercise of stock options | 41,233 |  |  | — |  |  | 274 |  |  | (17,032) |  |  | 112 |  |  | — |  |  | 386 |
Issuance of restricted stock | — |  |  | — |  |  | (73) |  |  | (11,080) |  |  | 73 |  |  | — |  |  | — |
Restricted stock shares canceled/forfeited | — |  |  | — |  |  | 185 |  |  | 28,112 |  |  | (185) |  |  | — |  |  | — |
Employee stock purchase plan | 209,390 |  |  | — |  |  | 688 |  |  | — |  |  | — |  |  | — |  |  | 688 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8,534 |  |  | 8,534 |
Balance at September 30, 2023 | 116,359,748 |  |  | $ | 116 |  |  | $ | 188,369 |  |  | — |  |  | $ | — |  |  | $ | (187,155) |  |  | $ | 1,330 |

7

| Common Stock Issued |  | Additional Paid- In |  | Treasury Stock |  | Accumulated |  |
| Shares |  | Amount |  | Capital |  | Shares |  | Amount |  | Deficit |  | Total
Balance at December 31, 2023 | 146,227,639 |  |  | $ | 146 |  |  | $ | 276,249 |  |  | — |  |  | $ | — |  |  | $ | (133,678) |  |  | $ | 142,717 |
Share-based compensation expense | — |  |  | — |  |  | 12,240 |  |  | — |  |  | — |  |  | — |  |  | 12,240 |
Employee stock purchase plan | 245,640 |  |  | — |  |  | 1,583 |  |  | — |  |  | — |  |  | — |  |  | 1,583 |
Issuance of restricted stock, net | 1,481,847 |  |  | 2 |  |  | (2,613) |  |  | — |  |  | — |  |  | — |  |  | (2,611) |
Exercise of stock options | 207,686 |  |  | — |  |  | 1,398 |  |  | — |  |  | — |  |  | — |  |  | 1,398 |
Shares received in settlement of litigation | (1,200,000) |  |  | (1) |  |  | (9,299) |  |  | — |  |  | — |  |  | — |  |  | (9,300) |
Net Income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 34,981 |  |  | 34,981 |
Balance at September 30, 2024 | 146,962,812 |  |  | $ | 147 |  |  | $ | 279,558 |  |  | — |  |  | $ | — |  |  | $ | (98,697) |  |  | $ | 181,008 |

| Common Stock Issued |  | Additional Paid- In |  | Treasury Stock |  | Accumulated |  |
| Shares |  | Amount |  | Capital |  | Shares |  | Amount |  | Deficit |  | Total
Balance at December 31, 2022 | 113,705,447 |  |  | $ | 114 |  |  | $ | 173,804 |  |  | — |  |  | $ | — |  |  | $ | (191,906) |  |  | $ | (17,988) |
Share-based compensation expense | — |  |  | — |  |  | 12,793 |  |  | — |  |  | — |  |  | — |  |  | 12,793 |
Exercise of stock options | 45,567 |  |  | — |  |  | 294 |  |  | (17,032) |  |  | 112 |  |  | — |  |  | 406 |
Restricted stock shares canceled/forfeited | — |  |  | — |  |  | 378 |  |  | 90,367 |  |  | (378) |  |  | — |  |  | — |
Employee stock purchase plan | 444,809 |  |  | — |  |  | 1,368 |  |  | — |  |  | — |  |  | — |  |  | 1,368 |
Issuance of restricted stock | 2,163,925 |  |  | 2 |  |  | (268) |  |  | (73,335) |  |  | 266 |  |  | — |  |  | — |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,751 |  |  | 4,751 |
Balance at September 30, 2023 | 116,359,748 |  |  | $ | 116 |  |  | 188,369 |  |  | — |  |  | $ | — |  |  | $ | (187,155) |  |  | $ | 1,330 |

See notes to unaudited condensed consolidated financial statements
8

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)
(unaudited)

| Nine Months Ended September 30,
| 2024 |  | 2023
Cash flows from operating activities: |  |  |
Net income (loss) from continuing operations | $ | 34,560 |  |  | $ | 16,151 |
Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by operating activities from continuing operations: |  |  |
Share-based compensation | 12,240 |  |  | 12,573 |
Fair value of shares received in settlement of litigation (Note 12) | (9,300) |  |  | — |
Change in deferred income taxes | 10,142 |  |  | — |
Depreciation | 1,715 |  |  | 2,054 |
Loss on extinguishment of debt | 1,401 |  |  | — |
Amortization of intangible assets | 1,336 |  |  | 570 |
Non-cash lease expenses | 972 |  |  | 959 |
Impairment of intangible assets | 352 |  |  | — |
Amortization of deferred financing costs | 219 |  |  | 373 |
Bad debt expense | 141 |  |  | 737 |
Other | 430 |  |  | 70 |
Increase (decrease) in cash resulting from changes in: |  |  |
Accounts receivable | (299) |  |  | (6,659) |
Inventory | (2,797) |  |  | (5,885) |
Prepaid expenses | 2,717 |  |  | 4,361 |
Other assets | (521) |  |  | 1,024 |
Accounts payable | (2,123) |  |  | 716 |
Accrued compensation | (600) |  |  | 1,932 |
Accrued expenses | (931) |  |  | (2,268) |
Other liabilities | (1,307) |  |  | (1,041) |
Net cash flows provided by operating activities from continuing operations | 48,347 |  |  | 25,667 |
Net cash flows used in operating activities from discontinued operations | (931) |  |  | (9,149) |
Net cash flows provided by operating activities | 47,416 |  |  | 16,518 |
Cash flows from investing activities: |  |  |
Consideration paid pursuant to TELA APA (Note 12) | (5,366) |  |  | — |
Purchases of equipment | (1,420) |  |  | (1,560) |
Patent application costs | (30) |  |  | (114) |
Net cash flows used in investing activities | (6,816) |  |  | (1,674) |
Cash flows from financing activities: |  |  |
Proceeds from Citizens Revolving Credit Facility | 30,000 |  |  | — |
Proceeds from Citizens Term Loan Facility | 19,783 |  |  | — |
Prepayment premium on Hayfin term loan | (500) |  |  | — |
Deferred financing cost | (1,101) |  |  | — |
Repayment of Hayfin term loan | (50,000) |  |  | — |
Repayment of Citizens Revolving Credit Facility | (30,000) |  |  | — |
Principal payments on Citizens Term Loan Facility | (750) |  |  | — |
Proceeds from exercise of stock options | 1,398 |  |  | 406 |
Stock repurchased for tax withholdings on vesting of restricted stock | (2,611) |  |  | — |
Principal payments on finance lease | (18) |  |  | (36) |
Net cash flows (used in) provided by financing activities | (33,799) |  |  | 370 |
Net change in cash | 6,801 |  |  | 15,214 |
Cash and cash equivalents, beginning of period | 82,000 |  |  | 65,950 |
Cash and cash equivalents, end of period | $ | 88,801 |  |  | $ | 81,164 |

See notes to unaudited condensed consolidated financial statements
9

MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
1.Nature of Business
MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of the Company’s products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).
The Company’s product portfolio and product development focuses on Wound and Surgical markets.
The Company’s business is focused primarily on the United States, but the Company also has an emerging commercial presence in several international locations, including Japan.
2.Significant Accounting Policies
Please see Note 2, Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 for a description of all significant accounting policies.
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three and nine months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.
Reclassifications
Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item, still within current liabilities, in the September 30, 2024 balance sheet presentation.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimates of fair value of and the probable achievement of performance conditions associated with share-based payment awards, estimates of returns and allowances, estimate of fair value of Profit Share Payments (as defined below), and valuation of deferred tax assets.
10

Intangible Assets, Net
Intangible assets are assets which lack physical substance and (a) grant the Company with a legal right or (b) are capable of being separated and sold. Intangible assets acquired outside of a business combination are capitalized based on the cost to acquire the assets, allocated pro rata based on the fair value of the individual assets acquired. Any contingent consideration issued in connection with the acquisition of assets is capitalized at the time at which all contingencies regarding its payment are resolved. The Company amortizes the capitalized cost of finite-lived intangible assets over a period generally reflective of the anticipated contributions to cash flow generation. Amortization of intangible assets is recorded as part of cost of sales or operating expenses in the unaudited condensed consolidated statements of operations depending on the nature of the underlying intangible asset and its use in the Company’s operations.
Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“ASC”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of September 30, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, “Improvement to Income Tax Disclosures (Topic 740)”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective as of September 30, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.
11

3. Accounts Receivable, Net
Accounts receivable, net, consisted of the following (in thousands):

| September 30, 2024 |  | December 31, 2023
Accounts receivable, gross | $ | 56,797 |  |  | $ | 57,015 |
Less: allowance for doubtful accounts | (2,767) |  |  | (3,144) |
Accounts receivable, net | $ | 54,030 |  |  | $ | 53,871 |

Activity related to the Company’s allowance for doubtful accounts for the three months ended September 30, 2024 and 2023 were as follows (in thousands):

| 2024 |  | 2023
Balance at July 1 | $ | 3,269 |  |  | $ | 2,196 |
Bad debt (reversal) expense | (279) |  |  | 447 |
Write-offs | (223) |  |  | (69) |
Balance at September 30 | $ | 2,767 |  |  | $ | 2,574 |

Activity related to the Company’s allowance for doubtful accounts for the nine months ended September 30, 2024 and 2023 were as follows (in thousands):

| 2024 |  | 2023
Balance at January 1 | $ | 3,144 |  |  | 3,783 |
Bad debt expense | 141 |  |  | 737 |
Write-offs | (518) |  |  | (1,946) |
Balance at September 30 | $ | 2,767 |  |  | $ | 2,574 |

4. Inventory
Inventory consisted of the following (in thousands):

| September 30, 2024 |  | December 31, 2023
Raw materials | $ | 781 |  |  | $ | 825 |
Work in process | 9,279 |  |  | 8,521 |
Finished goods | 14,189 |  |  | 11,675 |
Inventory | $ | 24,249 |  |  | $ | 21,021 |

5. Property and Equipment, Net
Property and equipment, net, consisted of the following (in thousands):

| September 30, 2024 |  | December 31, 2023
Laboratory and clean room equipment | $ | 15,568 |  |  | $ | 13,954 |
Furniture and equipment | 1,972 |  |  | 1,989 |
Leasehold improvements | 8,199 |  |  | 8,141 |
Construction in progress | 910 |  |  | 1,791 |
Asset retirement cost | 881 |  |  | 938 |
Finance lease right-of-use asset | 189 |  |  | 189 |
Property and equipment, gross | 27,719 |  |  | 27,002 |
Less: accumulated depreciation and amortization | (21,268) |  |  | (20,028) |
Property and equipment, net | $ | 6,451 |  |  | $ | 6,974 |

12

6. Intangible Assets, Net
Intangible assets, net, are summarized as follows (in thousands):

| September 30, 2024 |  | December 31, 2023
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount |  | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount
Amortized intangible assets |  |  |  |  |  |  |
Patents and know-how | $ | 10,207 |  | $ | (8,307) |  | $ | 1,900 |  |  | $ | 10,039 |  | $ | (7,818) |  | $ | 2,221 |
Licenses | 1,000 |  | (92) |  | 908 |  |  | 1,000 |  | (54) |  | $ | 946 |
Distribution rights | 7,659 |  | (765) |  | 6,894 |  |  | — |  | — |  | — |
Total amortized intangible assets | $ | 18,866 |  | $ | (9,164) |  | $ | 9,702 |  |  | $ | 11,039 |  | $ | (7,872) |  | $ | 3,167 |
Unamortized intangible assets: |  |  |  |  |  |  |
Tradenames and trademarks | $ | 1,008 |  |  | $ | 1,008 |  |  | $ | 1,008 |  |  | $ | 1,008 |
Patents in Process | 491 |  |  | 491 |  |  | 1,082 |  |  | 1,082 |
Total intangible assets | $ | 20,365 |  |  | $ | 11,201 |  |  | $ | 13,129 |  |  | $ | 5,257 |

The Company recognized $0.3 million and $0.4 million of impairment of intangible assets during the three and nine months ended September 30, 2024, respectively, related to abandoned patents.
Expected future amortization of intangible assets as of September 30, 2024, is as follows (in thousands):

Year ending December 31, | Estimated Amortization Expense
2024 (excluding the nine months ended September 30, 2024) | $ | 577 |
2025 | 1,912 |
2026 | 1,757 |
2027 | 1,757 |
2028 | 1,755 |
Thereafter | 1,944 |
Total amortized intangible assets | $ | 9,702 |

7. Accrued Expenses
Accrued expenses consisted of the following (in thousands):

| September 30, 2024 |  | December 31, 2023
Commissions to sales agents | $ | 3,154 |  |  | $ | 4,136 |
Accrued rebates | 1,806 |  |  | 745 |
Estimated sales returns | 912 |  |  | 1,096 |
Legal and settlement costs | 756 |  |  | 834 |
Accrued group purchasing organization fees | 688 |  |  | 1,338 |
Accrued travel | 587 |  |  | 433 |
Other | 493 |  |  | 779 |
Accrued expenses | $ | 8,396 |  |  | $ | 9,361 |

8. Long Term Debt, Net
13

Citizens Credit Agreement
On January 19, 2024 (the “Closing Date”), the Company entered into a Credit Agreement (the “Citizens Credit Agreement”) with certain lenders party thereto, and Citizens Bank, N.A., as administrative agent (the “Agent”). The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Credit Facilities”). All obligations are required to be paid in full on January 19, 2029 (the “Maturity Date”). The Company has the option to obtain one or more incremental Term Loan Facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times the Company’s Consolidated EBITDA (as defined therein), each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.
At the Company’s option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.
The Company is required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.88% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility on the Closing Date, with the remainder due on the Maturity Date. The Company must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment rights. The Company may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. The Company must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants. As of September 30, 2024, the Company is in compliance with all financial covenants under the Citizens Credit Agreement.
On the Closing Date, the Company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under the Company’s prior senior secured term loan with Hayfin (the “Hayfin Term Loan”) and to pay related fees, premiums, costs and expenses. The Company recorded a loss on extinguishment of debt of $1.4 million. This amount is reflected as a part of interest expense, net on the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2024. The composition of the loss on extinguishment of debt was as follows (amounts in thousands):

| January 19, 2024
Unamortized deferred financing costs | $ | 781 |
Unamortized original issue discount | 120 |
Prepayment premium | 500 |
Loss on extinguishment of debt | $ | 1,401 |

In addition, on February 27, 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of September 30, 2024. Deferred financing costs and original issue discount allocated to the Revolving Credit Facility are amortized straight-line through the expiration of the commitment term. The Revolving Credit Facility is currently subject to a commitment fee of 0.25% per annum of the amount undrawn, which is recognized as interest expense.
Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):
14

| January 19, 2024 |
| Term Loan Facility |  | Revolving Credit Facility |  | Total |
| Long term debt, net |  | Other assets |  |  |
Original issue discount | $ | 224 |  |  | $ | 839 |  |  | $ | 1,063 |  |
Deferred financing costs | 54 |  |  | 202 |  |  | 256 |  |

The balances of the Term Loan Facility as of September 30, 2024 and the Hayfin Term Loan as of December 31, 2023 were as follows (in thousands):

| September 30, 2024 |  | December 31, 2023 |  |
| Current portion of long term debt |  | Long term debt, net |  | Current portion of long term debt |  | Long term debt, net |  |
Outstanding principal | $ | 1,000 |  |  | $ | 18,250 |  |  | $ | 1,000 |  |  | $ | 49,000 |  |  |
Deferred financing costs | — |  |  | (42) |  |  | — |  |  | (781) |  |  |
Original issue discount | — |  |  | (190) |  |  | — |  |  | (120) |  |  |
Long term debt, net | $ | 1,000 |  |  | $ | 18,018 |  |  | $ | 1,000 |  |  | $ | 48,099 |  |  |

The Term Loan Facility bears interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR, as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The applicable margin is determined based on the Company’s consolidated total net leverage ratio. The Term Loan Facility carried an interest rate of 7.9% as of September 30, 2024. Interest expense related to the Term Loan Facility and the Hayfin Term Loan included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2023 |  | 2024 |  | 2023 |  |
Stated interest | $ | 393 |  |  | $ | 1,554 |  |  | 1,451 |  |  | $ | 4,498 |  |  |
Amortization of deferred financing costs | 5 |  |  | 111 |  |  | 38 |  |  | 323 |  |  |
Accretion of original issue discount | 12 |  |  | 17 |  |  | 36 |  |  | 50 |  |  |
Interest expense | $ | 410 |  |  | $ | 1,682 |  |  | $ | 1,525 |  |  | $ | 4,871 |  |  |

Interest expense related to the Revolving Credit Facility included in Interest income (expense), net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2024 |  |
Commitment fee | $ | 47 |  |  | $ | 125 |  |  |
Amortization of deferred financing costs | 16 |  |  | 47 |  |  |
Accretion of original issue discount | 42 |  |  | 126 |  |  |
Interest expense | $ | 105 |  |  | $ | 298 |  |  |

15

A summary of principal payments due on the Term Loan Facility, by year, from September 30, 2024 through maturity are as follows (in thousands):

Year ending December 31, | Principal
2024 (excluding the nine months ended September 30, 2024) | $ | 250 |
2025 | 1,000 |
2026 | 1,500 |
2027 | 1,500 |
2028 | 2,000 |
Thereafter | 13,000 |
Outstanding principal | $ | 19,250 |

As of September 30, 2024, the fair value of the Term Loan Facility was $19.7 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to September 30, 2024 using this discount rate.
9. Net Income Per Common Share
Net income per common share is calculated using two methods: basic and diluted.
Basic Net Income Per Common Share
The following table provides a reconciliation of net income from continuing operations and calculation of basic net income (loss) per common share for each of the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share amounts):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Net income from continuing operations | $ | 7,878 |  |  | $ | 8,842 |  |  | $ | 34,560 |  |  | $ | 16,151 |
Income (loss) from discontinued operations, net of tax | 217 |  |  | (308) |  |  | 421 |  |  | (11,400) |
Net income | 8,095 |  |  | 8,534 |  |  | 34,981 |  |  | 4,751 |
Accumulated dividend on previously converted Series B Preferred Stock | — |  |  | 1,773 |  |  | — |  |  | 5,184 |
Net income available to common stockholders from continuing operations | $ | 7,878 |  |  | $ | 7,069 |  |  | $ | 34,560 |  |  | $ | 10,967 |
Weighted average common shares outstanding | 146,958,986 |  |  | 116,298,146 |  |  | 147,008,732 |  |  | 115,528,067 |
Basic net income (loss) per common share: |  |  |  |  |  |  |
Continuing operations | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.24 |  |  | $ | 0.09 |
Discontinued operations | 0.00 |  |  | (0.00) |  |  | 0.00 |  |  | (0.09) |
Basic net income per common share | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.24 |  |  | $ | 0.00 |

16

Diluted Net Income Per Common Share
The following table sets forth the computation of diluted net income per common share (in thousands, except share and per share amounts):

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2023 |  | 2024 |  | 2023 |  |  |  |
Net income available to common stockholders from continuing operations | $ | 7,878 |  |  | $ | 7,069 |  |  | $ | 34,560 |  |  | $ | 10,967 |  |  |  |  |
Adjustments: |  |  |  |  |  |  |  |  |  |  |
Dividends on Series B Preferred Stock | — |  |  | 1,773 |  |  | — |  |  | 5,184 |  |  |  |  |
Less: antidilutive adjustments | — |  |  | — |  |  | — |  |  | (5,184) |  |  |  |  |
Total adjustments | — |  |  | 1,773 |  |  | — |  |  | — |  |  |  |  |
Numerator |  |  |  |  |  |  |  |  |  |  |
Net income available to common stockholders from continuing operations | 7,878 |  |  | 8,842 |  |  | 34,560 |  |  | 10,967 |  |  |  |  |
Income (loss) from discontinued operations, net of tax | 217 |  |  | (308) |  |  | 421 |  |  | (11,400) |  |  |  |  |
Weighted average shares outstanding | 146,958,986 |  |  | 116,298,146 |  |  | 147,008,732 |  |  | 115,528,067 |  |  |  |  |
Adjustments: |  |  |  |  |  |  |  |  |  |  |
Potential common shares (a) |  |  |  |  |  |  |  |  |  |  |
Series B Preferred Stock | — |  |  | 30,445,997 |  |  | — |  |  | — |  |  |  |  |
Restricted stock unit awards | 881,237 |  |  | 1,845,832 |  |  | 1,433,335 |  |  | 1,219,776 |  |  |  |  |
Outstanding stock options | 394,767 |  |  | 1,131,410 |  |  | 450,168 |  |  | 107,897 |  |  |  |  |
Performance stock unit awards | 114,050 |  |  | 35,441 |  |  | 57,629 |  |  | 13,425 |  |  |  |  |
Employee stock purchase plan | 24,591 |  |  | 1,113 |  |  | 14,924 |  |  | 372 |  |  |  |  |
Restricted stock awards | — |  |  | 15,767 |  |  | — |  |  | 23,733 |  |  |  |  |
Total adjustments | 1,414,645 |  |  | 33,475,560 |  |  | 1,956,056 |  |  | 1,365,203 |  |  |  |  |
Weighted average shares outstanding adjusted for potential common shares | 148,373,631 |  |  | 149,773,706 |  |  | 148,964,788 |  |  | 116,893,270 |  |  |  |  |
Diluted net income (loss) per common share: |  |  |  |  |  |  |  |  |  |  |
Continuing operations | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.23 |  |  | $ | 0.09 |  |  |  |  |
Discontinued operations | 0.00 |  |  | (0.00) |  |  | $ | 0.00 |  |  | (0.09) |  |  |  |  |
Diluted net income per common share | $ | 0.05 |  |  | $ | 0.06 |  |  | $ | 0.23 |  |  | $ | 0.00 |  |  |  |  |

(a) Weighted average common shares outstanding for the calculation of diluted net income per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2023 |  | 2024 |  | 2023 |  |  |  |
Series B Preferred Stock | — |  |  | — |  |  | — |  |  | 29,559,946 |  |  |  |  |

10. Income Taxes
On a continuing operations basis, the effective tax rates for the Company were 31.0% and 6.3% for the three months ended September 30, 2024 and 2023, respectively. On a continuing operating basis, the effective tax rates for the Company were 24.9% and 3.4% for the nine months ended September 30, 2024 and 2023, respectively.
Effective tax rates for the three and nine months ended September 30, 2023 were impacted by a full valuation allowance against the Company’s deferred tax assets. During the fourth quarter of 2023, the Company concluded that it was no longer in a cumulative three-year loss on a continuing operations basis, after excluding the effects of permanent book-tax differences. The absence of such negative evidence, coupled with its expectations for future taxable income generation, led to a change in the Company’s assessment of the realizability of its deferred tax assets. Consequently, effective tax rates for the three and nine months ended September 30, 2024 were not influenced by a valuation allowance.
17

Restricted stock vestings favorably impacted the effective tax rate for each of the three and nine ended September 30, 2024, partially offset by the executive compensation deduction limitation.
11. Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and non-cash activities are as follows (in thousands):

| Nine Months Ended September 30,
| 2024 |  | 2023
Cash paid for interest | $ | 2,297 |  |  | $ | 4,496 |
Cash paid for income taxes | 4,833 |  |  | 210 |
Non-cash activities: |  |  |
Fair value of shares received in settlement of litigation | 9,300 |  |  | — |
Minimum Profit Share Payments pursuant to TELA APA | 2,731 |  |  | — |
Right of use assets arising from operating lease liabilities | 1,820 |  |  | — |
Issuance of shares pursuant to employee stock purchase plan | 1,583 |  |  | 1,368 |
Purchases of equipment in accounts payable | — |  |  | 126 |

12. Commitments and Contingencies
TELA and Regenity Agreements
On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States. TELA held these rights pursuant to a Manufacturing and Supply Agreement (the “TELA-Regenity Supply Agreement”) between TELA and Regenity Biosciences, Inc. (“Regenity”), which retains all intellectual property rights and regulatory clearances related to the product. Pursuant to the TELA APA, the Company paid $5.0 million of initial consideration to TELA; additionally, the Company paid $0.4 million to acquire TELA’s remaining product inventory, and will be required to make additional payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two years following its commercialization of the product, which occurred during the second quarter of 2024.
In connection with the execution of the TELA APA, the Company was able to renegotiate the terms of the TELA-Regenity Supply Agreement, ultimately replacing it with a new Manufacturing and Supply Agreement (the “Supply Agreement”) with Regenity. The Supply Agreement maintains MIMEDX’s exclusive right to sell and market the product in the United States.
The transaction was accounted for as an acquisition of assets, as substantially all the fair value of the acquired assets was concentrated in the acquired exclusive distribution rights. The cost to acquire the assets on the transaction date was $8.1 million, reflecting the $5.0 million of initial consideration, $0.4 million to acquire inventory, and $2.7 million, which represented the fair value of the minimum amount of the Profit Share Payments. These costs were allocated amongst the assets acquired. The Company assigned $7.6 million to the distribution rights acquired and $0.5 million to inventory. The amount ascribed to the distribution rights will be amortized over five years, generally reflective of the period of time over which the distribution rights are anticipated to contribute to cash flow generation.
Any Profit Share Payments exceeding the $3.0 million minimum will be capitalized in the period incurred as a part of the acquired assets and amortized over the remaining life of such assets.
As of September 30, 2024, the fair value for the minimum amount of Profit Share Payments was $2.8 million. This amount reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium, all of which reflect Level 3 inputs. This amount is reflected as part of current portion of Profit Share Payments in the unaudited condensed consolidated balance sheet.
Litigation and Regulatory Matters
In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the
18

eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of September 30, 2024 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 16, “Commitments and Contingencies” in the 2023 Form 10-K.
The Company has no accrual for potential losses related to legal matters as of September 30, 2024. The Company made $0.6 million payments toward the resolution of legal matters involving the Company during the nine months ended September 30, 2024. The Company paid $0.2 million toward the resolution of legal matters during the nine months ended September 30, 2023.
In addition, in the quarter ended June 30, 2024, the Company received 1.2 million shares of its own common stock in the settlement of certain legal matters. The Company accounted for the repayment of shares as a loss recovery, as the repayment related to the recoupment of legal fees previously incurred, but not in excess of the amount originally recorded. The Company recorded $9.3 million, reflecting the fair value of the returned shares on the date of the prevailing agreement, as a reduction to investigation, restatement and related expense on the unaudited condensed consolidated statements of operations, where the legal fees to which this recovery originally related were recorded as they were incurred, for the nine months ended September 30, 2024.
The following is a description of certain litigation and regulatory matters to which the Company is a party:
Welker v. MiMedx et. al.
On November 4, 2022, Troy Welker and Min Turner, former option holders of the Company, brought a lawsuit in Fulton County State Court against the Company, former directors Terry Dewberry and Charles Evans, and former officers Parker H. “Pete” Petit, William C. Taylor, and Michael Senken alleging violations of the Georgia Racketeer Influenced and Corrupt Organizations (“RICO”) Act against all defendants, and conspiracy to violate the Georgia RICO Act and breach of fiduciary duty against the individual defendants. In August 2024, the parties reached a settlement and the matter is resolved.
AXIOFILL
The Company received a determination letter in March 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination. On March 25, 2024, MIMEDX filed suit in the U.S. District Court for the Northern District of Georgia against the FDA, the U.S. Department of Health and Human Services, Xavier Becerra, in his official capacity as Secretary of Health and Human Services, and Robert Califf, M.D. in his official capacity as Commissioner of Food and Drugs at FDA alleging violations of the Administrative Procedure Act and asking the Court to vacate FDA’s designation, declare FDA’s designation as arbitrary, capricious, an abuse of discretion, and contrary to law, and declare that AXIOFILL meets the criteria to be regulated under Section 361 of the Public Health Services Act. The parties have each filed motions for summary judgment in the case; briefing on the motions is expected to be completed by November 7, 2024.
13. Revenue
Net Sales by Site of Service
MIMEDX has three main sites of service for its products (1) Hospital settings and wound care clinics, which are stable reimbursement settings in which products are used for both wound and surgical applications, (2) Private offices, which generally represents doctors and practitioners with independent operations treating wound patients, and (3) Other, which includes federal facilities, international sales, and other sites of service using products for both wound and surgical applications.
Below is a summary of net sales by site of service (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2023 |  | 2024 |  | 2023 |  |  |  |
Hospital | $ | 46,034 |  |  | $ | 47,350 |  |  | $ | 137,174 |  |  | $ | 136,108 |  |  |  |  |
Private Office | 25,585 |  | 22,951 |  | 82,874 |  | 68,188 |  |  |  |
Other | 12,438 |  | 11,411 |  | 35,924 |  | 30,349 |  |  |  |
Total | $ | 84,057 |  |  | $ | 81,712 |  |  | $ | 255,972 |  |  | 234,645 |  |  |  |

19

Net Sales by Product Category
MIMEDX has two product categories: (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline based upon opportunities in each of these settings.
Below is a summary of net sales by product line (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2024 |  | 2023 |  | 2024 |  | 2023 |  |  |  |
Wound | $ | 55,052 |  |  | $ | 51,156 |  |  | $ | 169,647 |  |  | $ | 149,681 |  |  |  |  |
Surgical | 29,005 |  |  | 30,556 |  |  | 86,325 |  |  | 84,964 |  |  |  |  |
Total | $ | 84,057 |  |  | $ | 81,712 |  |  | $ | 255,972 |  |  | $ | 234,645 |  |  |  |  |

The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three or nine months ended September 30, 2024 or 2023.
14. Discontinued Operations
Disbanding of Regenerative Medicine Business Unit
In the second quarter of 2023, the Company announced the disbanding of its Regenerative Medicine reportable segment and the suspension of its Knee Osteoarthritis clinical trial program. The announcement reflected the abandonment of the Company’s efforts to pursue a Biological License Application for its micronized dehydrated human amnion chorion membrane product and a major definitive strategic shift in the Company’s focus towards its continuing commercial pipeline as its primary source of value creation.
The Company completed the regulatory obligations associated with the clinical trial during the fourth quarter of 2023, at which time material run-off operations had ceased and Regenerative Medicine met the criteria for presentation as a discontinued operation.
Financial Statement Impact of Discontinued Operations
The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023 as follows (in thousands):

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Selling, general and administrative expense | $ | (217) |  |  | $ | — |  |  | $ | (221) |  |  | $ | — |
Research and development expense | — |  |  | 100 |  |  | (200) |  |  | 7,937 |
Restructuring expense | — |  |  | 208 |  |  | — |  |  | 3,463 |
Income (loss) from discontinued operations | $ | 217 |  |  | $ | (308) |  |  | $ | 421 |  |  | $ | (11,400) |

20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
Executive Summary
During the third quarter of 2024, the Company delivered 2.9% growth in net sales year-over-year. Growth in the third quarter was seen in private office sites and was relatively balanced between Wound & Surgical products. In particular, the Company saw growth of its EPIEFFECT® and AMNIOEFFECT® products and initial contributions associated with sales of our recently launched HELIOGEN® product, partially offset by commercial challenges associated with recent turnover of certain of our sales team and customers, declines in sales of AXIOFILL® and the conclusion of sales of our dental product during the third quarter 2023.
Operational and financial highlights during the quarter included:
•Net sales of $84.1 million, reflecting 2.9% growth over the prior year period.
•GAAP net income from continuing operations and net income margin for the third quarter of 2024 of $7.9 million and 9.4%, respectively.
•Showcased leading allograft portfolio and latest scientific and clinical evidence at Symposium on Advanced Wound Care (SAWC) Fall.
•Highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds in The New York Times.
Overview
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of experience helping clinicians manage acute and chronic wounds, MIMEDX has been dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. All of our products sold in the United States are regulated by the U.S. Food & Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.
This discussion, which presents our results for the three and nine months ended September 30, 2024 and 2023, should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q and the financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
21

Results of Operations
Three Months Ended September 30, 2024 Compared to the Three Months Ended September 30, 2023

| Three Months Ended September 30, |
| (in thousands) |
| 2024 |  | 2023 |  | $ Change |  | % Change |
Net sales | $ | 84,057 |  |  | $ | 81,712 |  |  | $ | 2,345 |  |  | 2.9 | % |
Cost of sales | 15,322 |  |  | 14,790 |  |  | 532 |  |  | 3.6 | % |
Gross profit | 68,735 |  |  | 66,922 |  |  | 1,813 |  |  | 2.7 | % |
Selling, general and administrative | 53,516 |  |  | 52,571 |  |  | 945 |  |  | 1.8 | % |
Research and development | 2,918 |  |  | 3,075 |  |  | (157) |  |  | (5.1) | % |
Investigation, restatement and related | 649 |  |  | (38) |  |  | 687 |  |  | nm |
Amortization of intangible assets | 192 |  |  | 190 |  |  | 2 |  |  | 1.1 | % |
Impairment of intangible assets | 298 |  |  | — |  |  | 298 |  |  | nm |
Interest income (expense), net | 278 |  |  | (1,680) |  |  | 1,958 |  |  | nm |
Other expense, net | (21) |  |  | (11) |  |  | (10) |  |  | 90.9 | % |
Income tax provision | (3,541) |  |  | (591) |  |  | (2,950) |  |  | nm |
Net income from continuing operations | 7,878 |  |  | 8,842 |  |  | (964) |  |  | (10.9) | % |

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.
Net Sales
We recorded net sales for the three months ended September 30, 2024 of $84.1 million, a $2.3 million, or 2.9%, increase compared to the three months ended September 30, 2023, in which we recognized net sales of $81.7 million.
Our sales by product line were as follows (amounts in thousands):

| Three Months Ended September 30, |  | Change |  |  |  |
| 2024 |  | 2023 |  | $ |  | % |  |  |  |  |  |  |  |
Wound | $ | 55,052 |  |  | $ | 51,156 |  |  | $ | 3,896 |  |  | 7.6 | % |  |  |  |  |  |  |  |
Surgical | 29,005 |  |  | 30,556 |  |  | (1,551) |  |  | (5.1) | % |  |  |  |  |  |  |  |
Total | $ | 84,057 |  |  | $ | 81,712 |  |  | $ | 2,345 |  |  | 2.9 | % |  |  |  |  |  |  |  |

Net sales of our Wound product portfolio were $55.1 million for the three months ended September 30, 2024, a $3.9 million or 7.6% increase compared to $51.2 million for the three months ended September 30, 2023. The increase was primarily driven by contributions from EPIEFFECT, partially offset by commercial challenges associated with competitive behavior in the marketplace as well as headwinds relating to turnover of certain of our sales team and customers.
Net sales of our Surgical products totaled $29.0 million for the three months ended September 30, 2024, reflecting a decrease of $1.6 million, or 5.1%, compared to $30.6 million for the three months ended September 30, 2023. Sales growth from certain Surgical products, particularly AMNIOEFFECT, as well as initial contributions associated with sales of our recently launched HELIOGEN product, were more than offset by challenges in certain regions where we have recently experienced higher than normal employee turnover and, to a lesser degree, by declines in sales of AXIOFILL during the quarter. In addition, Surgical sales for the three months ended September 30, 2023 includes $1.4 million of sales of our dental product which we have since discontinued.
Cost of Sales and Gross Profit Margin
Cost of sales for the three months ended September 30, 2024 and 2023 was $15.3 million and $14.8 million, respectively, an increase of $0.5 million, or 3.6%, year-over-year. Gross profit margin for the three months ended September 30, 2024 was 81.8% compared to 81.9% for the three months ended September 30, 2023. Increases in cost of sales were driven by increases in sales volume. The year-over-year reduction in gross margin was driven by the amortization of distribution rights stemming from the TELA Asset Purchase Agreement entered into during the first quarter of 2024, as described below. This was partially offset by favorable product mix and our continued execution on yield and scrap improvement projects.
22

Selling, General and Administrative Expense
Selling, general and administrative (“SG&A”) expense for the three months ended September 30, 2024 was $53.5 million, compared to $52.6 million for the three months ended September 30, 2023, an increase of $0.9 million, or 1.8%, year-over-year. The increase in SG&A expense was driven by year-over-year increases in compensation related to higher salary and benefit costs from merit raises and promotions, as well as commissions driven by increases in sales volumes and proportionally higher sales through sales agents. Incremental spend from legal and regulatory disputes in the current period also contributed to the increase, including our ongoing litigation with a competitor and several former employees.
Research and Development Expense
Our research and development (“R&D”) expense for the three months ended September 30, 2024 was $2.9 million, compared to $3.1 million for the three months ended September 30, 2023, an decrease of $0.2 million. R&D spend in the quarter was driven, in part, by the randomized controlled trial for EPIEFFECT and ongoing investments in the development of future products in our pipeline.
Investigation, Restatement and Related Expense (Benefit)
Investigation, restatement and related expense for the three months ended September 30, 2024 was an expense of $0.6 million compared to an immaterial benefit for the three months ended September 30, 2023. The increase resulted from a negotiated reductions in legal fees previously incurred under indemnification agreements with certain former members of management during the three months ended September 30, 2023. This was offset by the last material payment towards the resolution of the historical Audit Committee investigation during the three months ended September 30, 2024. We do not expect activity to be material in future periods.
Amortization of Intangible Assets
Amortization expense related to intangible assets was $0.2 million for each of the three months ended September 30, 2024 and 2023.
Impairment of Intangible Assets
Impairment for the three months ended September 30, 2024 was $0.3 million, which relates to abandoned patents.
Interest Income (Expense), Net
Interest income, net was $0.3 million for the three months ended September 30, 2024 compared to a net interest expense of $1.7 million for the three months ended September 30, 2023. The decrease in interest expense was the result of a reduction in outstanding debt, lower interest rates under the new Citizens Credit Facilities compared to our previous borrowings, and improvements in our treasury management.
Income Tax Provision Expense
The effective tax rates for the Company were 31.0% and 6.3% for the three months ended September 30, 2024 and September 30, 2023, respectively.
The effective tax rate for the three months ended September 30, 2023 reflected a valuation allowance against all of the Company’s deferred tax assets. During the fourth quarter of 2023, we concluded that we were no longer in a cumulative three-year loss on a continuing operations basis, after excluding the effects of permanent book-tax differences. The absence of such negative evidence, coupled with our expectations for future taxable income generation, led to a change in our assessment of the realizability of our deferred tax assets. The effective tax rate for the three months ended September 30, 2024 was not influenced by a valuation allowance against deferred tax assets, which had an unfavorable impact on the effective tax rate.
The effective tax rate for the three months ended September 30, 2024 was favorably impacted by restricted stock vestings, offset by executive compensation deduction limitations.
Nine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023
23

| Nine Months Ended September 30,
| (in thousands)
| 2024 |  | 2023 |  | $ Change |  | % Change
Net sales | $ | 255,972 |  |  | $ | 234,645 |  |  | $ | 21,327 |  |  | 9.1 | %
Cost of sales | 43,164 |  |  | 40,792 |  |  | 2,372 |  |  | 5.8 | %
Gross profit | 212,808 |  |  | 193,853 |  |  | 18,955 |  |  | 9.8 | %
Selling, general and administrative | 164,044 |  |  | 156,773 |  |  | 7,271 |  |  | 4.6 | %
Research and development | 8,770 |  |  | 10,232 |  |  | (1,462) |  |  | (14.3) | %
Investigation, restatement and related | (8,741) |  |  | 4,652 |  |  | (13,393) |  |  | nm
Amortization of intangible assets | 572 |  |  | 570 |  |  | 2 |  |  | 0.4 | %
Impairment of intangible assets | 352 |  |  | — |  |  | 352 |  |  | nm
Interest expense, net | (1,409) |  |  | (4,864) |  |  | 3,455 |  |  | (71.0) | %
Other expense, net | (357) |  |  | (42) |  |  | (315) |  |  | nm
Income tax provision expense | (11,485) |  |  | (569) |  |  | (10,916) |  |  | nm
Net income from continuing operations | $ | 34,560 |  |  | $ | 16,151 |  |  | $ | 18,409 |  |  | nm

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.
Net Sales
We recorded net sales for the nine months ended September 30, 2024 of $256.0 million, a $21.3 million, or 9.1%, increase compared to the nine months ended September 30, 2023, for which we recorded net sales of $234.6 million.
Our sales by product were as follows (amounts in thousands):

| Nine Months Ended September 30, |  | Change
| 2024 |  | 2023 |  | $ |  | %
Wound | $ | 169,647 |  |  | $ | 149,681 |  |  | $ | 19,966 |  |  | 13.3 | %
Surgical | 86,325 |  | 84,964 |  | 1,361 |  |  | 1.6 | %
Total | $ | 255,972 |  |  | $ | 234,645 |  |  | $ | 21,327 |  |  | 9.1 | %

Net sales of our Wound product portfolio were $169.6 million for the nine months ended September 30, 2024, a $20.0 million or 13.3% increase compared to $149.7 million for the nine months ended September 30, 2023. The increase was primarily driven by contributions from EPIEFFECT, which did not have comparative sales for the nine months ended September 30, 2023, partially offset by commercial challenges associated with competitive behavior in the marketplace.
Net sales of our Surgical products totaled $86.3 million, reflecting growth of $1.4 million, or 1.6%, compared to the nine months ended September 30, 2023. The increase was primarily driven by growing volume contributions from AMNIOEFFECT and AMNIOFIX, as well as initial contributions associated with sales of our recently launched HELIOGEN product, partially offset by lower sales of AXIOFILL compared to the prior year period. In addition, Surgical sales for the nine months ended September 30, 2023 reflects approximately $3 million of sales of our dental product which we have since discontinued.
Cost of Sales and Gross Profit Margin
Cost of sales for the nine months ended September 30, 2024 was $43.2 million, an increase of $2.4 million, or 5.8%, compared to $40.8 million for the nine months ended September 30, 2023. Gross profit margin for the nine months ended September 30, 2024 was 83.1% compared to 82.6% for the nine months ended September 30, 2023. Increases in cost of sales were driven by increases in sales volume. The year-over-year improvement in gross margin was driven by favorable product mix and our continued execution on yield and scrap improvement projects, partially offset by the amortization of distribution rights stemming from the TELA Asset Purchase Agreement entered into during the first quarter of 2024.
Selling, General and Administrative Expense
Selling, general and administrative expenses for the nine months ended September 30, 2024 increased $7.3 million, or 4.6%, to $164.0 million, compared to $156.8 million for the nine months ended September 30, 2023. The increase in SG&A expenses
24

was driven by year-over-year increases in compensation related to higher salary and benefit costs from merit raises and promotions, as well as commissions driven by increases in sales volumes and proportionally higher sales through sales agents. Incremental spend from legal and regulatory disputes in the current period also contributed to the increase, including our ongoing litigation with a competitor and several former employees.
Research and Development Expense
Our research and development expenses decreased $1.5 million, or 14.3%, to $8.8 million for the nine months ended September 30, 2024, compared to $10.2 million for the nine months ended September 30, 2023. This decrease was driven primarily by lower headcount and the timing of R&D activities compared to the prior year.
Investigation, Restatement and Related Expense
Investigation, restatement and related expenses for the nine months ended September 30, 2024 was a benefit of $8.7 million compared to expense of $4.7 million for the nine months ended September 30, 2023. The benefit resulted from various settlements related to former officers and other related matters as well as negotiated reductions in legal fees previously incurred under indemnification agreements with certain former members of management during the nine months ended September 30, 2023. This was offset by the last material payment towards the resolution of our historical Audit Committee investigation during the nine months ended September 30, 2024. We do not expect activity to be material in future periods .
Amortization of Intangible Assets
Amortization expense related to intangible assets was $0.6 million for each of the nine months ended September 30, 2023 and 2023.
Impairment of Intangible Assets
Impairment for the nine months ended September 30, 2024 was $0.4 million, which relates to abandoned patents.
Interest Expense, Net
Interest expense, net was $1.4 million for the nine months ended September 30, 2024 compared to $4.9 million for the nine months ended September 30, 2023. The decrease was the result of a decrease in outstanding debt, lower interest rates under the Citizens Credit Facilities, and improvements in our treasury management. The decrease was partially offset by a loss on extinguishment of debt due to repaying and terminating a previous loan agreement during the first quarter of 2024 ($1.4 million).
Income Tax Provision Expense
The effective tax rates for the Company were 24.9% and 3.4% for the nine months ended September 30, 2024 and 2023, respectively.
During the fourth quarter of 2023, we noted that we were no longer in a cumulative three-year loss on a continuing operations basis, after excluding the effects of permanent book-tax differences. The absence of such negative evidence, coupled with our expectations for future taxable income generation, led to a change in our assessment of the realizability of our deferred tax assets. Consequently, the effective tax rate for the nine months ended September 30, 2024 was not influenced by a valuation allowance reflected against deferred tax assets, which had an unfavorable impact on the effective tax rate.
The effective tax rate for the nine months ended September 30, 2024 was favorably impacted by vestings of restricted stock units, offset by executive compensation deduction limitations.
Discussion of Cash Flows
Operating Activities
Net cash provided by operating activities from continuing operations during the nine months ended September 30, 2024 was $47.4 million, compared to cash provided by operating activities from continuing operations of $16.5 million for the nine months ended September 30, 2023. The change was primarily the result of year-over-year increases in net sales, which drove increases in collections from customers.
Investing Activities
25

Net cash used for investing activities during the nine months ended September 30, 2024 was $6.8 million, compared to $1.7 million for the nine months ended September 30, 2023. This increase was largely the result of our investment to expand our product portfolio through the TELA and Regenity agreements, as described below in “Liquidity and Capital Resources.”
Financing Activities
Net cash used for financing activities during the nine months ended September 30, 2024 was $33.8 million. Cash provided by financing activities was $0.4 million during the nine months ended September 30, 2023. The cash used during the nine months ended September 30, 2024 was due to the repayment of the initial $30.0 million drawing under the Revolving Credit Facility, as described below in “Liquidity and Capital Resources,” deferred financing costs and other payments made as part of the Debt Refinancing Transactions, as defined below, and stock repurchases for tax withholdings upon vesting of employee stock awards.
Liquidity and Capital Resources
We require capital for our operating activities, including costs associated with the sale of product through direct and indirect sales channels, research and development activities, compliance costs, costs to sell and market our products, regulatory fees, and legal and consulting fees in connection with ongoing litigation and other matters. We generally fund our operating capital requirements through our operating activities and cash reserves. We expect to use capital to invest in the broadening of our product portfolio, including through potential acquisitions, licensing agreements or other arrangements, the international expansion of our business and certain capital projects.
As of September 30, 2024, we had $88.8 million of cash and cash equivalents, total current assets of $172.1 million and total current liabilities of $41.9 million, reflecting a current ratio of 4.1. We had no borrowings outstanding and $75 million of availability under our Revolving Credit Facility (as defined below).
The Company is currently paying its obligations in the ordinary course of business. We believe that our cash from operating activities, existing cash and cash equivalents, and available credit under the Citizens Credit Agreement, as defined below, will enable us to meet our operational liquidity needs for the twelve months following the filing date of this Quarterly Report.
Citizens Credit Facilities
On January 19, 2024, we entered into a Credit Agreement (the “Citizens Credit Agreement”) with a syndicate of banks comprised of Citizens Bank, N.A. as administrative agent (the “Agent”), and Bank of America, N.A. The Citizens Credit Agreement was designed to simultaneously improve our capital structure, providing the ability to refinance our prior $50 million senior secured term loan under the Hayfin Loan Agreement (as defined below) at lower interest rates and have access to additional borrowing capacity that could be deployed in the future in support of our organic and potential inorganic growth objectives.
The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Credit Facilities”). All obligations are required to be paid in full on January 19, 2029 (the “Maturity Date”), and are guaranteed by certain of our subsidiaries, and secured by substantially all of the assets of the Company and the guarantors pursuant to a customary security agreement. Subject to the terms of the Citizens Credit Agreement, we have the option to obtain one or more incremental term loan facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times our Consolidated EBITDA as defined therein, each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.
At our option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.
We are required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.875% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility at inception, with the remainder due on the Maturity Date. We must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment
26

rights. We may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. We must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants. As of September 30, 2024, the Company is in compliance with all financial covenants under the Credit Facilities.
On January 19, 2024, we borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities, together with cash on hand, were used to repay in full the $50.0 million principal amount and other obligations under that certain Loan Agreement, dated as of June 30, 2020 (as amended from time to time), by and among the Company, the guarantors party thereto, the lenders party thereto and Hayfin Services LLP, as administrative and collateral agent (as amended from time to time, the “Hayfin Loan Agreement”) and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”).
On February 27, 2024, we repaid the initial $30.0 million drawing under the Revolving Credit Facility.
Contractual Obligations
Except as described below, there were no significant changes to our contractual obligations during the nine months ended September 30, 2024 from those disclosed in the section Item 7, “Management’s Discussion and Analysis of Financial Condition and Results from Operations”, in our 2023 Form 10-K.
TELA and Regenity Agreements
On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) and a manufacturing and supply agreement (the “Supply Agreement”) with Regenity Biosciences, Inc. (“Regenity”), adding to the Company’s product portfolio a 510(k)-cleared collagen particulate xenograft product now marketed as HELIOGEN (“HELIOGEN”) indicated for the management of moderately to heavily exudating wounds and to control minor bleeding. Under the terms of the TELA APA, the Company made an initial $5.0 million payment to TELA and will be required to make additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million, based on net sales of HELIOGEN over the next two years from June 2024.
The Supply Agreement maintains MIMEDX’s exclusive right to sell and market HELIOGEN in the United States and requires MIMEDX to purchase a minimum amount of HELIOGEN from Regenity annually through December 31, 2033. Should MIMEDX fail to meet a purchasing minimum in any one period, it has the option (among others) to amend its distribution rights under the Supply Agreement to be non-exclusive.
Critical Accounting Estimates
In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of critical accounting estimates in preparing the financial statements was provided in our 2023 Form 10-K.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2, Significant Accounting Policies, to the unaudited condensed consolidated financial statements contained herein.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to risks associated with changes in interest rates that could adversely affect our results of operations and financial condition. We do not hedge against interest rate risk.
The interest rate on our Term Loan Facility is determined quarterly based on the 1-month term SOFR. As of September 30, 2024, the interest rate on our Term Loan Facility was 7.9%. A 100 basis point change in SOFR would change our interest expense by $0.2 million on an annualized basis.
27

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
28

PART II – OTHER INFORMATION
Item 1. Legal Proceedings
The Company and its subsidiaries are parties to numerous claims and lawsuits arising in the ordinary course of its business activities, some of which involve claims for substantial amounts. The ultimate outcome of these suits cannot be ascertained at this time. The description of the Welker v. MiMedx, et. Al case, which was settled in August 2024, contained in Note 12, “Commitments and Contingencies,” to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report, is incorporated herein by reference.
Item 1A. Risk Factors
There have been no material changes to the Company’s risk factors included in its 2023 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) None.
(b) None.
(c) The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchases (as defined in Exchange Act Rule 10b-18) during the three month period ended September 30, 2024:

| Total number of shares purchased 1 |  | Average price paid per share |  | Total number of shares purchased under publicly announced plan |  | Approximate dollar value of shares that may yet be purchased under plans or programs
July 1 - July 31, 2024 | 31,380 |  |  | $ | 7.18 |  |  | — |  |  | $ | — |
August 1 - August 31, 2024 | — |  |  | — |  |  | — |  |  | — |
September 1 - September 30, 2024 | — |  |  | — |  |  | — |  |  | — |
Total for the quarter | 31,380 |  |  | $ | 7.18 |  |  | $ | — |  |  | $ | — |

(1) Reflect repurchases of shares by the Company upon vesting of employee restricted stock units in order to satisfy tax withholding obligations.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Insider Trading Arrangements and Policies
During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
29

Item 6. Exhibits

Exhibit Number |  | Description
31.1 # |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 # |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 # |  | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 # |  | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS # |  | XBRL Instance Document
101.SCH # |  | XBRL Taxonomy Extension Schema Document
101.CAL # |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF # |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB # |  | XBRL Taxonomy Extension Label Linkbase Document
101.PRE # |  | XBRL Taxonomy Extension Presentation Linkbase Document

* | Previously filed and incorporated herein by reference
# | Filed or furnished herewith

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

October 30, 2024 | MIMEDX GROUP, INC.
| By: | /s/ Doug Rice
|  | Doug Rice
|  | Chief Financial Officer
|  | (duly authorized officer)

30